ONE ASSAY TO TEST THEM ALL: COMPARING MULTIPLEX ASSAYS FOR EXPANSION OF RESPIRATORY VIRUS SURVEILLANCE.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
22 Jan 2023
Historique:
entrez: 30 1 2023
pubmed: 31 1 2023
medline: 31 1 2023
Statut: epublish

Résumé

Molecular multiplex assays (MPAs) for simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza and respiratory syncytial virus (RSV) in a single RT-PCR reaction reduce time and increase efficiency to identify multiple pathogens with overlapping clinical presentation but different treatments or public health implications. Clinical performance of XpertXpress The three MPAs confidently detect all lineages of SARS-CoV-2 and influenza viruses. MPA-LoDs vary from 1-2 Log10 differences from SoC depending on assay and strain. Clinical evaluation resulted in overall agreement between 97% and 100%, demonstrating a high accuracy to detect all targets. Existing differences in costs, testing burden and implementation constraints influence the choice in primary or community settings. TP, PC and GX, reliably detect SARS-CoV-2, influenza and RSV simultaneously, with reduced time-to-results and simplified workflows. MPAs have the potential to enhancediagnostics, surveillance system, and epidemic response to drive policy on prevention and control of viral respiratory infections. Viral respiratory infections represent a major burden globally, weighed down by the COVID-19 pandemic, and threatened by spillover of novel zoonotic influenza viruses. Since respiratory infections share clinical presentations, identification of the causing agent for patient care and public health measures requires laboratory testing for several pathogens, including potential zoonotic spillovers. Simultaneous detection of SARS-CoV-2, influenza, and RSV in a single RT-PCR accelerates time from sampling to diagnosis, preserve consumables, and streamline human resources to respond to other endemic or emerging pathogens. Multiplex assays have the potential to sustain and even expand surveillance systems, can utilize capacity/capability developed during the COVID-19 pandemic worldwide, thereby strengthening epidemic/pandemic preparedness, prevention, and response.

Sections du résumé

Background UNASSIGNED
Molecular multiplex assays (MPAs) for simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza and respiratory syncytial virus (RSV) in a single RT-PCR reaction reduce time and increase efficiency to identify multiple pathogens with overlapping clinical presentation but different treatments or public health implications.
Methods UNASSIGNED
Clinical performance of XpertXpress
Results UNASSIGNED
The three MPAs confidently detect all lineages of SARS-CoV-2 and influenza viruses. MPA-LoDs vary from 1-2 Log10 differences from SoC depending on assay and strain. Clinical evaluation resulted in overall agreement between 97% and 100%, demonstrating a high accuracy to detect all targets. Existing differences in costs, testing burden and implementation constraints influence the choice in primary or community settings.
Conclusion UNASSIGNED
TP, PC and GX, reliably detect SARS-CoV-2, influenza and RSV simultaneously, with reduced time-to-results and simplified workflows. MPAs have the potential to enhancediagnostics, surveillance system, and epidemic response to drive policy on prevention and control of viral respiratory infections.
IMPORTANCE OBJECTIVE
Viral respiratory infections represent a major burden globally, weighed down by the COVID-19 pandemic, and threatened by spillover of novel zoonotic influenza viruses. Since respiratory infections share clinical presentations, identification of the causing agent for patient care and public health measures requires laboratory testing for several pathogens, including potential zoonotic spillovers. Simultaneous detection of SARS-CoV-2, influenza, and RSV in a single RT-PCR accelerates time from sampling to diagnosis, preserve consumables, and streamline human resources to respond to other endemic or emerging pathogens. Multiplex assays have the potential to sustain and even expand surveillance systems, can utilize capacity/capability developed during the COVID-19 pandemic worldwide, thereby strengthening epidemic/pandemic preparedness, prevention, and response.

Identifiants

pubmed: 36711477
doi: 10.1101/2023.01.19.23284806
pmc: PMC9882628
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI151758
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Arch Intern Med. 2007 Feb 26;167(4):354-60
pubmed: 17242309
China CDC Wkly. 2021 Oct 29;3(44):937-940
pubmed: 34745695
Virol J. 2021 Jun 14;18(1):127
pubmed: 34127006
Lancet Child Adolesc Health. 2022 Feb;6(2):106-115
pubmed: 34800370
Emerg Infect Dis. 2021 Oct;27(10):2742-2745
pubmed: 34546164
J Clin Virol. 2017 Aug;93:25-29
pubmed: 28600949
J Virol Methods. 2021 Dec;298:114304
pubmed: 34592335
J Gen Virol. 2021 Mar;102(3):
pubmed: 33416462
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
J Infect Dis. 2021 May 28;223(10):1666-1670
pubmed: 33580259
Ther Adv Respir Dis. 2021 Jan-Dec;15:1753466621995050
pubmed: 33749408
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33436456
J Med Virol. 2021 Oct;93(10):5798-5804
pubmed: 34050951
Virol J. 2015 Feb 08;12:18
pubmed: 25889293
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33298613
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Elife. 2016 Jun 28;5:
pubmed: 27350259
Clin Infect Dis. 2019 Mar 5;68(6):e1-e47
pubmed: 30566567
Clin Infect Dis. 2021 Nov 2;73(9):e2829-e2830
pubmed: 33594407
Expert Rev Mol Diagn. 2018 Jul;18(7):631-643
pubmed: 29886764
J Med Virol. 2020 Apr;92(4):408-417
pubmed: 31944312
JAMA. 2020 May 19;323(19):1969-1971
pubmed: 32275293

Auteurs

Narjis Boukli (N)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Claude Flamand (C)

Epidemiology Unit, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Kim Lay Chea (KL)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Leangyi Heng (L)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Seangmai Keo (S)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Kimhoung Sour (K)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Sophea In (S)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Panha Chhim (P)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Bunthea Chhor (B)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Lomor Kruy (L)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Jelena D M Feenstra (JDM)

Thermo Fisher Scientific, South San Francisco CA, United States.

Manoj Gandhi (M)

Thermo Fisher Scientific, South San Francisco CA, United States.

Obiageli Okafor (O)

Thermo Fisher Scientific, South San Francisco CA, United States.

Camilla Ulekliev (C)

Thermo Fisher Scientific, South San Francisco CA, United States.

Heidi Auerswald (H)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Viseth Srey Horm (VS)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Erik A Karlsson (EA)

Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

Classifications MeSH